Get the Stockscreener App
43.05
1.69%
-0.74
Pre-market:
43.00
-0.05
-0.12%
Xenon Pharmaceuticals Inc stock is traded at $43.05, with a volume of 1.13M.
It is down -1.69% in the last 24 hours and up +4.62% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$43.79
Open:
$44.64
24h Volume:
1.13M
Relative Volume:
1.28
Market Cap:
$3.33B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-15.71
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
-3.42%
1M Performance:
+4.62%
6M Performance:
+11.41%
1Y Performance:
+19.52%
1-Day Range:
$42.31
$44.64
1-Week Range:
$41.32
$46.99
52-Week Range:
$26.74
$46.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
43.05 | 3.38B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Investors Purchase High Volume of Xenon Pharmaceuticals Call Options (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Aug Selloffs: Does Xenon Pharmaceuticals Inc stock have upside surprise potentialJuly 2025 Short Interest & Long Hold Capital Preservation Plans - baoquankhu1.vn
Xenon awaiting critical epilepsy drug study results that could lead to FDA approval - The Globe and Mail
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - Defense World
Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program - TipRanks
Xenon Pharmaceuticals registers $400M of common shares for ATM offering - TradingView
Xenon Pharmaceuticals (XENE) refreshes $400,000,000 ATM share program - Stock Titan
Xenon Pharmaceuticals (NASDAQ: XENE) registers up to $400M ATM equity offering - Stock Titan
Needham & Company LLC Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month HighWhat's Next? - MarketBeat
Wedbush Adjusts Xenon Pharmaceuticals PT to $47 From $44, Maintains Outperform Rating - marketscreener.com
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - Finviz
Xenon Pharmaceuticals stock hits 52-week high at $46.68 - Investing.com
Xenon Pharmaceuticals stock hits 52-week high at $46.68 By Investing.com - Investing.com Canada
Westfield Capital Management Co. LP Boosts Stake in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative - Sahm
Decoding Xenon Pharmaceuticals Inc (XENE): A Strategic SWOT Insi - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Xenon Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Xenon Pharmaceuticals: Q4 Earnings Snapshot - Barchart.com
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
JPMorgan Chase & Co. Buys 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
XENE Technical Analysis & ETF Price Forecast - Intellectia AI
Xenon Pharmaceuticals (NASDAQ:XENE) Earns Outperform Rating from Analysts at Wolfe Research - Defense World
Xenon earnings loom as investors brace for Phase 3 catalyst By Investing.com - Investing.com Canada
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded at Wolfe Research - MarketBeat
Xenon Pharmaceuticals Inc. (XENE) Investor Outlook: Analyzing a 30% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
A Look At Xenon Pharmaceuticals (XENE) Valuation After Wolfe Research’s New Favorable Coverage - Yahoo Finance
Wolfe Research initiates Xenon Pharmaceuticals stock coverage with outperform rating - Investing.com Nigeria
XENE: Xenon Pharmaceuticals Coverage Initiated by Wolfe Research - GuruFocus
Wolfe Research Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Investment Review: Will DRMA stock go up in YEAR2025 Winners & Losers & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Will Xenon Pharmaceuticals Inc. stock benefit from green energy trends2025 Fundamental Recap & Risk Controlled Daily Plans - mfd.ru
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Is Xenon Pharmaceuticals (NASDAQ:XENE) Rising In The Nasdaq Index - Kalkine Media
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data - Nasdaq
Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Thursday - MarketBeat
Is Xenon Pharmaceuticals Inc. a speculative investmentJuly 2025 Rallies & Weekly Market Pulse Alerts - mfd.ru
Aberdeen Group plc Has $23.25 Million Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Understanding Momentum Shifts in (XENE) - Stock Traders Daily
How Xenon Pharmaceuticals Inc. stock reacts to global recession fearsInsider Buying & Safe Swing Trade Setups - mfd.ru
Activity Recap: Is Xenon Pharmaceuticals Inc stock undervalued right nowWeekly Trade Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Is Xenon Pharmaceuticals Inc. stock a safe haven assetIPO Watch & Precise Swing Trade Entry Alerts - mfd.ru
Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
How Xenon Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Levels & Real-Time Price Movement Reports - mfd.ru
Xenon Pharma To Report Epilepsy Trial Results Next Month - RTTNews
Is Xenon Pharmaceuticals Inc. a strong candidate for buy and holdPortfolio Gains Report & Fast Gaining Stock Reports - mfd.ru
Xenon Pharmaceuticals Inc. (XENE) Investor Outlook: Strong Buy Ratings and 31.57% Potential Upside - DirectorsTalk Interviews
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):